

NOTICE

ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

99113768	<i>Ipratropium bromide/ salbutamol sulfate</i>		120 dose(s)	20 mcg/100 mcg /dose	Sol. Inh.		
----------	--	--	----------------	-------------------------	-----------	--	--

until the following medications, appearing on the *List of Medications* attached to the *Regulation respecting the List of medications covered by the basic prescription drug insurance plan*, are no longer out of stock:

02232570	<i>Airomir</i>	Valeant	200 dose(s)	100 mcg/ dose	Oral aerosol	5.00	
02245669	<i>Apo-Salvent sans CFC</i>	Apotex	200 dose(s)	100 mcg/ dose	Oral aerosol	5.00	
02326450	<i>Novo-Salbutamol HFA</i>	Novopharm	200 dose(s)	100 mcg/ dose	Oral aerosol	5.00	
02419858	<i>Salbutamol HFA</i>	Sanis	200 dose(s)	100 mcg/ dose	Oral aerosol	5.00	
02241497	<i>Ventolin HFA</i>	GSK	200 dose(s)	100 mcg/ dose	Oral aerosol	6.00	

This notice has effect retroactively from 24 April 2020.

Québec, 12 May 2020

[original signed by]

MARCO THIBAUT
President and Chief Executive Officer
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.